Beijing Gene Key Completes Patient Enrollment in Phase 1b Trial of GKL-006, an iNKT Cell Therapy for Hepatocellular Carcinoma, in Combination with TACE
Phase 1b Trial of Next-Generation Invariant NKT Cell Therapy GKL-006 Commences
Beijing Gene Key Life Technology, a Chinese biotech company, has initiated a Phase 1b clinical trial (NCT07713290) of its invariant NKT (iNKT) cell therapy, 'GKL-006 Injection,' for patients with unresectable hepatocellular carcinoma (HCC). The trial has successfully enrolled and registered the initial cohort of six patients. This study, conducted under the approval of China's National Medical Products Administration (NMPA), will evaluate a combination therapy of GKL-006 and transarterial chemoembolization (TACE) in six patients with locally advanced (CNLC II~IIIa stage) HCC. The trial aims to assess the synergistic effect of immune cell therapy and local treatment in patients with HCC who are not candidates for surgical resection.
Improving the Immune Microenvironment through TACE Combination Therapy and Clinical Design
TACE is a local treatment that blocks blood flow to HCC tumors and directly injects anti-cancer drugs, inducing tumor necrosis. However, it also has the limitation of creating a locally immunosuppressive environment. GKL-006 is designed to reverse immune suppression within the tumor microenvironment (TME) and induce a potent anti-tumor immune response. It is based on iNKT cells, which possess the characteristics of both natural killer (NK) cells and T cells. The trial, which began in April 2025, aims to collect safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) data, with a primary endpoint evaluation deadline of November 2026. It will also explore the objective response rate (ORR) and progression-free survival (PFS) based on mRECIST criteria.
Growing Hepatocellular Carcinoma Treatment Market and Limitations of Existing Standard Treatments
The global HCC treatment market is projected to grow from approximately USD 3.6 billion in 2024 to USD 9.8 billion in 2030, with an annual growth rate of over 18%. Currently, the standard of care (SoC) includes combination therapies such as Roche's Tecentriq (Atezolizumab) + Avastin (Bevacizumab) or AstraZeneca's Imfinzi (Durvalumab) + Imjudo (Tremelimumab). However, a significant number of patients still experience resistance or recurrence at the locally advanced stage. Therefore, early combination strategies involving lymph-inducing local treatments like TACE and next-generation immune cell therapies are gaining attention as potential game-changers in the market.
Achievement of Clinical Milestone and Expectations for Future Partnerships
This study is actively tracking patients with a target final clinical completion date of February 2027, and the collected immune biomarker data will serve as a key basis for the design of subsequent Phase 2 and Phase 3 trials. iNKT cell therapy has the potential for both autologous and allogeneic administration, making it an alternative to overcome the limitations of existing CAR-T therapies, such as high cost and poor solid tumor penetration. If meaningful safety profiles and early tumor suppression efficacy are demonstrated in the initial Phase 1b trial, discussions regarding licensing agreements and large-scale joint development partnerships with global pharmaceutical companies are expected to proceed rapidly.
With the global HCC market projected to reach USD 9.8 billion by 2030, this Phase 1b trial (NCT07713290) targets patients with unresectable CNLC II~IIIa stage HCC, who have limited options with existing treatments such as Lenvatinib and Atezolizumab+Bevacizumab. The combination of TACE local treatment and iNKT cell therapy GKL-006 represents a novel mechanism to overcome immune suppression in the tumor microenvironment, and the Phase 1 data, expected in November 2026, will be a key milestone. The results from this trial, involving six patients worldwide, will be pivotal in demonstrating the commercial and clinical viability of the iNKT platform, which offers improved solid tumor penetration compared to CAR-T. If meaningful progression-free survival (PFS) data is observed after the final clinical completion in February 2027, the value of Beijing Gene Key Life Technology for future investment rounds and potential licensing deals with global pharmaceutical companies is expected to increase significantly.
Source: ClinicalTrials.gov (api_ct)